Novartis’ Cell-based Vaccine: Seasonal Approval With Pandemic Implications
This article was originally published in The Pink Sheet Daily
The Flucelvax flu vaccine is the first approved in the U.S. that is derived from cell-based technology instead of the traditional egg-based process. It will be made at Novartis’ Holly Springs, N.C. plant.
You may also be interested in...
CDC’s Advisory Committee on Immunization Practices adds four recently-approved flu vaccines to its recommended list of products, but the committee chair expresses doubt that there could ever be data to make preferential recommendations.
Agency asks for comments to help it formulate a strategic plan to mitigate and prevent drug shortages, including ideas for incentives to increase manufacturing capacity and promote increased quality.
The trivalent vaccine can be produced much faster than traditional vaccines and could be modified to compete with quadrivalent formulations.